Conditions: Esophageal Neoplasms; Adenocarcinoma of the Gastroesophageal Junction; Gastroesophageal Cancer; Squamous Cell Carcinoma; Gastric Adenocarcinoma
Interventions: Drug: DKN-01 150 mg; Drug: Paclitaxel; Drug: Pembrolizumab; Drug: DKN-01 300 mg
Sponsors: Leap Therapeutics, Inc.; Merck Sharp & Dohme LLC
Completed
Interventions: Drug: DKN-01 150 mg; Drug: Paclitaxel; Drug: Pembrolizumab; Drug: DKN-01 300 mg
Sponsors: Leap Therapeutics, Inc.; Merck Sharp & Dohme LLC
Completed
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
